Voleon Capital Management LP Boosts Stock Holdings in Ironwood Pharmaceuticals, Inc. $IRWD

Key Points

• Voleon Capital Management LP increased its stake in Ironwood Pharmaceuticals by 952.4%, acquiring an additional 787,901 shares, bringing its total ownership to 870,629 shares valued at approximately $1.28 million.
• Ironwood Pharmaceuticals reported an earnings per share (EPS) of $0.14 for the last quarter, significantly surpassing analysts' expectations of ($0.02), and generated $85.24 million in revenue.
• Wall Street Zen upgraded Ironwood Pharmaceuticals' stock rating from "hold" to "strong-buy," with an average target price set at $4.94.

Voleon Capital Management LP boosted its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 952.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 870,629 shares of the biotechnology company's stock after purchasing an additional 787,901 shares during the period. Voleon Capital Management LP owned about 0.54% of Ironwood Pharmaceuticals worth $1,280,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the company. Deutsche Bank AG lifted its position in shares of Ironwood Pharmaceuticals by 47.4% during the fourth quarter. Deutsche Bank AG now owns 1,567,535 shares of the biotechnology company's stock worth $6,944,000 after acquiring an additional 504,336 shares in the last quarter. GSA Capital Partners LLP lifted its position in shares of Ironwood Pharmaceuticals by 3,683.6% during the first quarter. GSA Capital Partners LLP now owns 524,676 shares of the biotechnology company's stock worth $771,000 after acquiring an additional 510,809 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter worth $1,888,000. Armistice Capital LLC lifted its position in shares of Ironwood Pharmaceuticals by 44.7% during the first quarter. Armistice Capital LLC now owns 13,700,000 shares of the biotechnology company's stock worth $20,139,000 after acquiring an additional 4,232,000 shares in the last quarter. Finally, Cerity Partners LLC bought a new position in shares of Ironwood Pharmaceuticals in the first quarter worth $142,000.

Ironwood Pharmaceuticals Trading Down 2.2%

Shares of NASDAQ:IRWD opened at $1.13 on Tuesday. The stock's 50-day moving average price is $0.94 and its 200-day moving average price is $0.98. Ironwood Pharmaceuticals, Inc. has a 12-month low of $0.53 and a 12-month high of $5.13. The stock has a market capitalization of $183.55 million, a P/E ratio of -22.60 and a beta of 0.32.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.02) by $0.16. The firm had revenue of $85.24 million for the quarter, compared to analysts' expectations of $62.02 million. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current year.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 9th. One analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $4.94.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.

Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.